A New Era in MASH: How Disease-Specific Therapies Are Changing the Game

MANCHESTER GRAND HYATT SAN DIEGO
1 Market Place | San Diego, CA 92101
Grand Ballroom B - Lobby Level
Room is located behind the check in area.

STATEMENT: This program is not affiliated with Digestive Disease Week®.

ACTIVITY OVERVIEW – Mitigating disease progression in MASH has been challenging due to a lack of disease-specific therapies. With FDA approval of the first MASH-specific therapy, and several other agents in advanced stages of development comes, a new era of disease management. This activity will explore the mechanism of action and efficacy of these novel therapies, including thyroid hormone receptor-β (THR-β) agonists, along with data on late-stage investigational therapies. Experts will also focus on case-based scenarios that discuss considerations for disease staging and assessment through non-invasive tests to ensure pharmacological management is tailored to the individual needs of each patient.

TARGET AUDIENCE – This initiative is intended for hepatology and gastroenterology healthcare providers, as well as other specialty clinicians involved in the management of patients with MASLD/MASH.

AGENDA

• Introduction. The Growing Burden of MASLD/MASH: A Call to Action
• Changing the MASH Paradigm with THR-β Agonists and Other Disease-specific Therapies
• Rising to the Need to Improve Diagnosis in the Era of Disease-specific Therapy
• Integrating MASLD/MASH-Specific Therapy into Guideline-Aligned Real-World Practice
• Q&A and Closing Remarks

LEARNING OBJECTIVES
Upon successful completion of this activity, participants should be better able to:

• Describe the mechanistic and clinical rationale for THR-b agonists as a means of treating MASLD/MASH
• Evaluate the evidence on THR-b agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
• Identify best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
• Develop guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.
This activity is supported by an educational grant from Madrigal Pharmaceuticals.
Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph*rm*cy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Type of Activity: Application-based

Fee Information: There is no fee for this educational activity

Host or Publisher Catalyst Medical Education, LLC